Kyntra Bio (KYNB) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue rose 14% year-over-year to $50.6 million, driven by strong roxadustat sales in China, offsetting declines in other segments and the termination of pamrevlumab after failing late-stage pancreatic cancer trials.

• Major cost reduction plan implemented, including a 75% reduction in U.S. headcount and winding down of pamrevlumab and immuno-oncology programs.

• Refocused R&D strategy on advancing FG-3246 (CD46-targeted ADC) for mCRPC, with positive Phase 1 results and Phase 2 trials planned for 2025.

• Roxadustat remains the primary value driver, maintaining leadership in China’s anemia of CKD market and expanding globally.

Financial highlights

• Q2 2024 total revenue was $50.6 million, up 14% year-over-year; net product revenue in China was $49.6 million, up 108% year-over-year.

• Net loss for Q2 2024 was $15.5 million ($0.16 per share), a significant improvement from $87.7 million ($0.90 per share) in Q2 2023.

• Cash, cash equivalents, and accounts receivable totaled $147.1 million as of June 30, 2024, supporting operations into 2026.

• Operating expenses for Q2 2024 were $61.6 million, down 53% year-over-year.

• Deferred revenue release of $18 million contributed to revenue growth.

Outlook and guidance

• Full-year 2024 net product revenue guidance raised to $135–$150 million, with China roxadustat net sales projected at $320–$350 million.

• Cash runway projected into 2026 based on current balances and cost reductions.

• Operating expenses (including COGS) expected to be $45–$55 million per quarter in H2 2024.

• Awaiting China approval decision for roxadustat in chemotherapy-induced anemia in H2 2024; potential $10 million milestone from AstraZeneca.

• Topline Phase 2 data for FG-3246 + enzalutamide in mCRPC expected 1H 2025; Phase 2 monotherapy study to initiate 1Q 2025.